Company information
- Ticker
- JACS
- Country
- United States
- Sector
- Financials
- Industry
- Others
Jackson Acquisition Co II Business Summary
Jackson Acquisition Co II (NYSE: JACS) is a special purpose acquisition company (SPAC) structured as a blank check vehicle to facilitate a merger, capital stock exchange, or asset acquisition. The company does not maintain traditional operational revenue segments; instead, its business model centers on leveraging its trust account capital—raised through a $230 million initial public offering in December 2024—to identify and integrate a high-growth target within the healthcare services or healthcare technology sectors. As of February 2026, JACS is actively scouting for private entities that can benefit from public market access, despite recently receiving an NYSE noncompliance notice regarding its minimum public stockholder count. Its primary competitors include other healthcare-focused or general-purpose SPACs such as Aldel Financial II (ALDF), GigCapital9 (GIXX.U), Roman DBDR Acquisition II (DRDB), and Live Oak Acquisition V (LOKV), against which JACS differentiates itself through its sponsor's deep domain expertise in healthcare staffing and clinical operations. The company is led by Chairman and CEO Richard L. "Rick" Jackson, a prominent healthcare entrepreneur who founded Jackson Healthcare, one of the nation’s largest healthcare staffing and technology organizations. Supporting him is CFO David Lawrence, who brings over 20 years of biotech financial leadership from roles at Neurotrauma Sciences and Acorda Therapeutics. The board of directors features a high-pedigree assembly of industry veterans, including James Nicholas Ayers (former Chief of Staff to the Vice President of the United States), Stephan Rodgers (former CEO of AccentCare), Paul Gabos (former CFO of Lincare Holdings), and Brian McCarthy (former Vice Chairman of Healthcare Investment Banking at Bank of America). Notable institutional backing includes positions from Wolverine Asset Management, Radcliffe Capital Management, and Goldman Sachs, providing the firm with significant institutional credibility as it pursues its initial business combination.